Sunday, 15 July 2012

Sibutramine Hydrochloride


Class: Anorexigenic Agents and Respiratory and Cerebral Stimulants, Miscellaneous
VA Class: GA751
Chemical Name: 1-(4-chlorophenyl)-N,N-dimethyl-α-(2-methylpropyl)-cyclobutanemethanamine hydrochloride monohydrate
Molecular Formula: C17H26ClN • HCl • H2O
CAS Number: 84485-00-7
Brands: Meridia


Special Alerts:


On October 8, 2010, the manufacturer announced a voluntary withdrawal of sibutramine from the US market.19 20 The withdrawal was requested by FDA following review of new data on cardiovascular risk.19 20 (See Cardiovascular Effects under Cautions.)


REMS:


FDA approved a REMS for sibutramine to ensure that the benefits of a drug outweigh the risks. The REMS may apply to one or more preparations of sibutramine and consists of the following: medication guide. See the FDA REMS page () or the ASHP REMS Resource Center ().



Introduction

Anorexigenic agent.1 4 7 9


Uses for Sibutramine Hydrochloride


Obesity


Adjunct to caloric restriction, increased physical activity, and behavioral modification in the management of exogenous obesity; used for weight loss and maintenance of weight loss.1 4 7 9 (See Special Alerts.)


Used in patients with initial body mass index (BMI) of ≥30 kg/m2; also used in those with BMI of ≥27 kg/m2 in the presence of risk factor or disease (e.g., adequately controlled hypertension, diabetes mellitus, dyslipidemia).1 4 7


Effect of sibutramine on the morbidity and mortality associated with obesity not established.1 2


Sibutramine Hydrochloride Dosage and Administration


General



  • Allow at least 2 weeks to elapse between discontinuance of an MAO inhibitor and initiation of sibutramine and vice versa.1 7



Administration


Oral Administration


Administer orally without regard to meals.1


Administered once daily in the morning in clinical studies.1


Dosage


Available as sibutramine hydrochloride monohydrate; dosage expressed in terms of the monohydrate.1 10


Adults


Obesity

Oral

Initially, 10 mg once daily.1


If weight loss is inadequate (e.g., <1.8 kg of weight loss) after 4 weeks of treatment, consider increasing dosage to 15 mg daily or discontinuance; take BP and heart rate into account.1 7


If weight loss during the first 3–6 months of therapy is <5% of the patient’s baseline body weight, FDA recommends discontinuance, since continued sibutramine therapy is unlikely to be effective and would expose the patient to unnecessary risks.17


Reserve 5-mg daily dose for patients who do not tolerate 10 mg daily.1


Safety and efficacy >2 years not established in clinical studies.1


Prescribing Limits


Adults


Obesity

Oral

Maximum 15 mg daily.1


Special Populations


Hepatic Impairment


Mild or moderate hepatic impairment: Dosage adjustment not needed.1 (See Special Populations under Pharmacokinetics.) Not recommended in severe hepatic impairment.1


Renal Impairment


Not recommended in severe renal impairment.1


Geriatric Patients


Contraindicated in patients >65 years of age.1


Cautions for Sibutramine Hydrochloride


Contraindications



  • History of CAD (e.g., angina, history of MI), CHF, tachycardia, peripheral arterial occlusive disease, cardiac arrhythmia, or cerebrovascular disease (stroke or TIA).1 (See Cardiovascular Effects under Cautions.)




  • Inadequately controlled hypertension (systolic/diastolic BP >145/90 mm Hg).1 (See Cardiovascular Effects under Cautions.)




  • Geriatric patients >65 years of age.1




  • Concurrent or recent (i.e., within 2 weeks) therapy with an MAO inhibitor.1 (See Drug Interactions under Cautions.)




  • Major eating disorder (e.g., anorexia nervosa, bulimia nervosa).1




  • Concurrent therapy with another centrally acting anorexigenic drug.1 (See Specific Drugs under Interactions.)




  • Known hypersensitivity to sibutramine or any ingredient in the formulation.1



Warnings/Precautions


Warnings


Cardiovascular Effects

Substantially increases BP and increases pulse in some patients, particularly when initiated at higher dosages.1 9 Monitoring of BP and pulse required prior to and at regular intervals during therapy.1 7 Consideration of decreased dosage or discontinuance recommended in patients with sustained increases in BP or pulse rate.1 7


Caution in patients with a history of hypertension.1 Should not be used in those with uncontrolled or poorly controlled hypertension.1


Contraindicated in patients with history of CAD (e.g., angina, history of MI), CHF, tachycardia, peripheral arterial occlusive disease, cardiac arrhythmia, or cerebrovascular disease (stroke or TIA).1


Increased risk of nonfatal MI and stroke reported in overweight or obese patients at increased risk for cardiovascular events (≥55 years of age, history of cardiovascular disease [CAD, peripheral arterial occlusive disease, or stroke] and/or type 2 diabetes mellitus, and ≥1 additional cardiovascular risk factor); effects on body weight relative to placebo were modest.15 16 17 19 21 FDA concluded that the modest increase in weight loss, in the absence of evidence of other associated health benefits, would be outweighed by even a small increase in risk of cardiovascular events.21 22 19 On October 8, 2010, the manufacturer voluntarily complied with FDA's request to voluntarily withdraw sibutramine from the US market.19 20


Health care professionals should stop prescribing and dispensing sibutramine and should contact patients currently taking the drug to inform them of the risks and advise them to stop taking the drug.19 Individuals receiving sibutramine therapy should stop taking the drug and discuss alternatives for weight loss or weight-loss maintenance with their clinician.19


Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)-like Reactions

Potentially life-threatening serotonin syndrome or NMS-like reactions reported during concurrent therapy with SSRIs or SNRIs and other serotonergic drugs (e.g., 5-HT1 receptor agonists [“triptans”]), drugs that impair serotonin metabolism (e.g., MAO inhibitors), or antipsychotics or other dopamine antagonists.1 (See Contraindications under Cautions and see Specific Drugs under Interactions.)


Symptoms of serotonin syndrome may include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile BP, hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination), and/or GI symptoms (e.g., nausea, vomiting, diarrhea).1


Severe serotonin syndrome may resemble NMS, which is characterized by hyperthermia, muscle rigidity, autonomic instability with possible rapid fluctuation of vital signs, and mental status changes.1


Monitor patients receiving sibutramine for the development of serotonin syndrome or NMS-like signs and symptoms.1 Serotonin syndrome requires immediate medical treatment.1


Drug Interactions

Concomitant use with MAO inhibitor associated with serotonin syndrome.1 7 (See Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)-like Reactions under Cautions and see Specific Drugs under Interactions.)


Glaucoma

May cause mydriasis; caution in patients with angle-closure (narrow-angle) glaucoma.1


Other Warnings

Exclude organic causes (e.g., untreated hypothyroidism) of obesity before initiating sibutramine.1


General Precautions


Pulmonary Hypertension

Pulmonary hypertension associated with anorexigenic drugs that induce serotonin release; risk with sibutramine unknown.1


Seizures

Seizures reported rarely.1 Caution in patients with history of seizures; discontinue if seizures occur.1 6


Bleeding

Bleeding events reported; causal relationship unclear.1 Caution in patients predisposed to bleeding and in those receiving drugs that affect hemostasis or platelet function.1


Cholelithiasis

Weight loss can exacerbate or precipitate gallstone formation.1


CNS Effects

Like other CNS-active drugs, may impair judgment, thinking, or motor skills.1


Specific Populations


Pregnancy

Category C.1 Use during pregnancy not recommended.1


Lactation

Not known whether sibutramine is distributed into milk.1 Use not recommended.1


Pediatric Use

Safety and efficacy in children <16 years of age not established.1


In one clinical study in obese adolescents, 2 patients reported suicidal ideation and one patient attempted suicide.1 Sibutramine inhibits reuptake of serotonin and norepinephrine similarly to the mechanism of some antidepressants; not known whether the drug increases the risk of suicidality in pediatric patients.1


Geriatric Use

Insufficient experience in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults; contraindicated in patients >65 years of age.1


Hepatic Impairment

Use not recommended in patients with severe hepatic impairment; not systematically evaluated in these individuals.1


Renal Impairment

Do not use in patients with severe renal impairment, including those with end-stage renal disease receiving dialysis.1 Use with caution in patients with mild or moderate renal impairment.1


Common Adverse Effects


Headache, dry mouth, anorexia, constipation, insomnia, rhinitis, pharyngitis, increased appetite, back pain, flu syndrome, accidental injury, asthenia, nausea, arthralgia, nervousness, dyspepsia, sinusitis.1 7 9


Interactions for Sibutramine Hydrochloride


Metabolized to active metabolites principally by CYP3A4.1 7


Drugs Affecting Hepatic Microsomal Enzymes


Pharmacokinetic interaction likely with drugs that inhibit CYP3A4 with possible alteration in the metabolism of sibutramine.1


Drugs Affecting Hemostasis or Platelet Function.


Possible increased risk of bleeding; caution advised.1


Protein-bound Drugs


Interaction unlikely.1


Specific Drugs













































Drug



Interaction



Comments



Alcohol



Pharmacologic interaction unlikely1 7


No clinically important psychomotor interactions reported in limited study1



Excessive alcohol consumption not recommended1 7



Cimetidine



Small increases in AUC and peak plasma concentrations of sibutramine metabolites1 7



CNS drugs



Potential pharmacologic interaction1



Caution advised1 7



Erythromycin



Decreased sibutramine metabolism; altered serum concentrations of sibutramine and its metabolites1 7



Ketoconazole



Decreased sibutramine metabolism; altered serum concentrations of sibutramine and its metabolites1 7



Lorazepam



No significant changes in pharmacokinetics of active sibutramine metabolites or lorazepam1



MAO inhibitors (e.g., phenelzine, selegiline)



Potentially fatal serotonin syndrome1 7



Concomitant use contraindicated1


Allow at least 2 weeks to elapse between discontinuance of the MAO inhibitor and initiation of sibutramine and vice versa1 7



Olanzapine



Increased peak plasma concentration and AUC of sibutramine and increased peak plasma concentration of its active secondary metabolite; no significant effect on olanzapine pharmacokinetics1



Omeprazole



Increased peak plasma concentration and AUC of sibutramine and its active secondary metabolite; no significant effect on omeprazole pharmacokinetics1



Oral contraceptives



Suppression of ovulation not inhibited1



Alternative contraceptive precautions not needed1 7



Serotonergic drugs (dihydroergotamine, lithium, opiate agonists [e.g., dextromethorphan, fentanyl, meperidine, pentazocine], sumatriptan, tryptophan, serotonin-reuptake inhibitors)



Potential for serotonin syndrome; potentially serious or fatal1 7



Sibutramine should not be used with other serotonergic agents; if such use is clinically indicated, monitor carefully1 7



Simvastatin



Decreased peak plasma concentrations and AUC of sibutramine and its active secondary metabolite; increased simvastatin acid AUC1



Sympathomimetic agents (ephedrine, pseudoephedrine)



Potential pharmacologic interaction with drugs that may increase BP and pulse1 7



Caution1 7


Sibutramine Hydrochloride Pharmacokinetics


Absorption


Bioavailability


Rapidly absorbed from the GI tract; undergoes extensive first-pass hepatic metabolism to active mono- and di-desmethyl metabolites (M1, M2).1


77% of a single oral dose is absorbed; absolute bioavailability undetermined.1


Food


Food reduces peak plasma concentrations of M1 and M2 by 27 and 32%, respectively, and delays time to peak plasma concentrations by about 3 hours but does not affect AUCs of M1 or M2.1


Special Populations


Geriatric patients: Plasma concentrations of M1 and M2 metabolites are similar to those in younger adults.1


Moderate hepatic impairment: Combined AUCs of M1 and M2 metabolites increased by 24% compared with values in healthy individuals.1


Moderate or severe renal impairment: AUC of M1 metabolite increased by 24–46% compared with values in healthy individuals.1 End-stage renal disease: AUC of M2 metabolite decreased by 50% in patients receiving dialysis compared with values in healthy individuals.1 AUCs of inactive M5 and M6 metabolites increased twofold to threefold or eightfold to 11-fold in patients with moderate or severe renal impairment, respectively, and increased 22- to 33-fold in those with end-stage renal disease receiving dialysis compared with values in healthy individuals.1


Distribution


Extent


Extensively distributed, highest concentration in liver and kidney.1


Plasma Protein Binding


Sibutramine: 97%.1


M1 and M2: 94% each.1


Elimination


Metabolism


Principally metabolized in the liver by CYP3A4 to active mono-desmethyl (M1) and di-desmethyl (M2) metabolites; then hydroxylated and conjugated to inactive metabolites (M5 and M6).1


Elimination Route


Excreted principally in urine (77%) as inactive metabolites and in feces.1


Half-life


Sibutramine: 1.1 hours.1


M1: 14 hours.1


M2: 16 hours.1


Stability


Storage


Oral


Capsules

25°C (may be exposed to 15–30°C).1 Protect from heat and moisture.1


Actions



  • Anorectic effects principally due to active metabolites (M1 and M2) that inhibit reuptake (but not release) of serotonin, norepinephrine, and, to a lesser extent, dopamine at the neuronal synapse, thus promoting a sense of satiety.1 2 3 7 9




  • Increase energy expenditure through thermogenic effects in animals: not confirmed in humans.3 7 10



Advice to Patients



  • Importance of reading the manufacturer’s patient information (medication guide) prior to beginning therapy and rereading it each time the prescription is renewed.1




  • Importance of informing clinician of the presence of, or any history of, cardiovascular disease, including CAD (e.g., angina, MI), CHF, tachycardia, peripheral arterial occlusive disease, cardiac arrhythmia, or cerebrovascular disease (stroke, TIA).6 Importance of informing clinician of any other concomitant disease (e.g., glaucoma, seizures, high BP, major eating disorder).6




  • Importance of immediately informing clinician if any signs or symptoms suggestive of cardiovascular disease (e.g., chest pain, palpitation, abnormal heart rate or rhythm) occur.19




  • Importance of notifying clinician if rash, urticaria, or other manifestations of allergic reaction occur.1




  • Importance of monitoring BP and pulse at regular intervals.1




  • Importance of not taking an extra dose if one is missed.6




  • Importance of informing clinician of existing or contemplated concomitant therapy, including prescription or OTC drugs, especially other drugs for promoting weight loss, decongestants, antidepressants, cough suppressants, lithium, dihydroergotamine, sumatriptan, or tryptophan because of potential for interactions.1




  • Potential for sibutramine to impair judgment, thinking, or motor skills; avoid driving or operating machinery until effects on the individual are known.1 6




  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.1




  • Importance of informing patients of other important precautionary information.1 (See Cautions.)



Preparations


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.


On October 8, 2010, the manufacturer announced a voluntary withdrawal of sibutramine from the US market.20 (See Cardiovascular Effects under Cautions.)























Sibutramine Hydrochloride

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Oral



Capsules



5 mg



Meridia (C-IV)



Abbott



10 mg



Meridia (C-IV)



Abbott



15 mg



Meridia (C-IV)



Abbott



Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.


The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions October 27, 2011. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.




References



1. Abbott. Meridia (sibutramine hydrochloride monohydrate) capsules prescribing information. North Chicago, IL; 2010 Aug.



2. Anon. Sibutramine for obesity. Med Lett Drugs Ther. 1998; 40:32. [PubMed 9529518]



3. Stock MJ. Sibutramine: a review of the pharmacology of a novel anti-obesity agent. Int J Obes Relat Metab Disord. 1997; 21(Suppl 1):S25-29. [PubMed 9130038]



4. National Institutes of Health, National Heart, Lung, and Blood Institute. Clinical Guidelines on the identification, evaluation and treatment of overweight and obesity in adults. The evidence report. Bethesda, MD; June 1998. From NHLBI web site.



5. Anon. American Heart Association urges caution on new diet drug. American Heart Association media advisory. Dallas, TX; 1997.



6. Abbott. Meridia (sibutramine hydrochloride monohydrate) capsules patient information. North Chicago, IL; 2010 Jan.



7. Luque CA, Rey JA. Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity. Ann Pharmacother. 1999; 33:968-78. [IDIS 436183] [PubMed 10492502]



8. Smith IG, Goulder MA. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract. 2001; 50:505-12. [PubMed 11407998]



9. Lean ME. Sibutramine—a review of clinical efficacy. Int J Obesity. 1997; 21:S30-6.



10. Abbott, Abbott Park, IL: Personal communication.



11. Baumgarten AH (US Food and Drug Administration Chicago District Office, Chicago, IL): Personal communication to White M (Abbott Laboratories, Abbott Park, IL); 2002 Jul 19.



12. Wolfe SH, Sasich LD, Barbehenn E (Public Citizen Health Research Group, Washington, DC): Personal communication to Thompson T (US Department of Health and Human Services, Washington DC); 2002 Mar 19.



13. Sun E (Abbott Laboratories, Abbott Park, IL): Personal communication to Thompson T (US Department of Health and Human Services, Washington DC); 2002 Jun 4.



15. James WPT. The SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients. Eur Heart J. 2005; 7(suppl L):L44-8.



16. Torp-Pedersen C, Caterson I, Coutinho W et al. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J. 2007; 28:2915-23. [PubMed 17595194]



17. Food and Drug Administration. Follow-up to the November 2009 early communication about an ongoing safety review of sibutramine, marketed as Meridia. Rockville, MD; 2010 Jan 21. From FDA website.



18. Food and Drug Administration. Early communication about an ongoing safety review of Meridia (sibutramine hydrochloride), Rockville, MD; 2009 Nov 20. From FDA website.



19. Food and Drug Administration. Drug safety communication: FDA recommends against the continued use of Meridia (sibutramine). Rockville, MD; 2010 Oct 8. From FDA website.



20. Abbott. Abbott to voluntarily withdraw Meridia (sibutramine) in the U.S. Abbott Park, IL; 2010 Oct 8. Press release from Abbott website.



21. Egan AG, Avigan M. Memorandum to the file, NDA 20-632, Meridia (sibutramine hydrochloride monohydrate). Rockville, MD: Food and Drug Administration; 2010 Oct 4. From FDA website.



22. Food and Drug Administration. Questions and answers: FDA recommends against the continued use of Meridia (sibutramine). Available from website. Accessed 2010 Oct 8.



More Sibutramine Hydrochloride resources


  • Sibutramine Hydrochloride Side Effects (in more detail)
  • Sibutramine Hydrochloride Dosage
  • Sibutramine Hydrochloride Use in Pregnancy & Breastfeeding
  • Sibutramine Hydrochloride Drug Interactions
  • Sibutramine Hydrochloride Support Group
  • 62 Reviews for Sibutramine Hydrochloride - Add your own review/rating


Compare Sibutramine Hydrochloride with other medications


  • Obesity

Saturday, 14 July 2012

Adriamycin


Generic Name: doxorubicin (Intravenous route)

dox-oh-ROO-bi-sin

Intravenous route(Solution;Powder for Solution)

Severe local tissue necrosis will occur if there is extravasation during administration; do not administer by the intramuscular or subcutaneous route. Myocardial toxicity manifested in its most severe form by potentially fatal congestive heart failure (CHF) may occur either during therapy or months to years after termination of therapy. The risk of developing CHF increases rapidly with increasing total cumulative doses of doxorubicin in excess of 400 mg/m(2). Secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) have been reported in patients treated with anthracyclines. Pediatric patients are also at risk for developing secondary AML. Reduce dosage in patients with impaired hepatic function. Severe myelosuppression may occur with therapy .



Commonly used brand name(s)

In the U.S.


  • Adriamycin

Available Dosage Forms:


  • Powder for Solution

  • Solution

Therapeutic Class: Antineoplastic Agent


Chemical Class: Anthracycline


Uses For Adriamycin


Doxorubicin belongs to the general group of medicines known as antineoplastics. It is used to treat some kinds of cancers of the blood; lymph system; bladder; breast; stomach; lung; ovaries; thyroid; nerves; kidneys; bones; and soft tissues, including muscles and tendons. It may also be used to treat other kinds of cancer, as determined by your doctor.


Doxorubicin seems to interfere with the growth of cancer cells, which are then eventually destroyed by the body. Since the growth of normal body cells may also be affected by doxorubicin, other effects will also occur. Some of these may be serious and must be reported to your doctor. Other effects, like hair loss, may not be serious but may cause concern. Some effects may not occur until months or years after the medicine is used.


Before you begin treatment with doxorubicin, you and your doctor should talk about the good this medicine will do as well as the risks of using it.


Doxorubicin is to be administered only by or under the supervision of your doctor.


Once a medicine has been approved for marketing for a certain use, experience may show that it is also useful for other medical problems. Although these uses are not included in product labeling, doxorubicin is used in certain patients with the following medical conditions:


  • Autoimmune deficiency syndrome (AIDS)–associated Kaposi's sarcoma (a type of cancer of the skin and mucous membranes that is more common in patients with AIDS)

  • Cancer of the adrenal cortex (the outside layer of the adrenal gland)

  • Cancer of the cervix

  • Cancer of the endometrium

  • Cancer of the esophagus

  • Cancers of the head and neck

  • Cancer of the liver

  • Cancer of the pancreas

  • Cancer of the prostate

  • Cancer of the thymus (a small organ found under the breast bone)

  • Carcinoid tumors

  • Chronic lymphocytic leukemia (a type of cancer of the blood and lymph system)

  • Ewing's sarcoma (a type of cancer found in the bone)

  • Gestational trophoblastic tumors (tumors in the uterus or womb)

  • Hepatoblastoma (a certain type of liver cancer that occurs in children)

  • Multiple myeloma (a certain type of cancer of the blood)

  • Non–small cell lung cancer (a certain type of lung cancer usually associated with prior smoking, passive smoking, or radon exposure)

  • Retinoblastoma (a type of eye cancer found primarily in children)

  • Tumors in the ovaries

Before Using Adriamycin


In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:


Allergies


Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.


Pediatric


Heart problems are more likely to occur in children younger than 2 years of age, who are usually more sensitive to the effects of doxorubicin.


Geriatric


Heart problems are more likely to occur in the elderly, who are usually more sensitive to the effects of doxorubicin. The elderly may also be more likely to have blood problems.


Pregnancy








Pregnancy CategoryExplanation
All TrimestersDStudies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy in a life threatening situation or a serious disease, may outweigh the potential risk.

Breast Feeding


Studies in women breastfeeding have demonstrated harmful infant effects. An alternative to this medication should be prescribed or you should stop breastfeeding while using this medicine.


Interactions with Medicines


Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are receiving this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.


Using this medicine with any of the following medicines is not recommended. Your doctor may decide not to treat you with this medication or change some of the other medicines you take.


  • Rotavirus Vaccine, Live

Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.


  • Adenovirus Vaccine Type 4, Live

  • Adenovirus Vaccine Type 7, Live

  • Bacillus of Calmette and Guerin Vaccine, Live

  • Cisplatin

  • Clozapine

  • Docetaxel

  • Glucosamine

  • Influenza Virus Vaccine, Live

  • Measles Virus Vaccine, Live

  • Mumps Virus Vaccine, Live

  • Paclitaxel

  • Rotavirus Vaccine, Live

  • Rubella Virus Vaccine, Live

  • Smallpox Vaccine

  • Stavudine

  • Trastuzumab

  • Typhoid Vaccine

  • Valspodar

  • Varicella Virus Vaccine

  • Warfarin

  • Yellow Fever Vaccine

  • Zidovudine

Using this medicine with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.


  • Cyclosporine

  • Eltrombopag

  • Phenytoin

  • Sorafenib

Interactions with Food/Tobacco/Alcohol


Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.


Other Medical Problems


The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:


  • Chickenpox (including recent exposure) or

  • Herpes zoster (shingles)—Risk of severe disease affecting other parts of the body

  • Gout or

  • Kidney stones—Doxorubicin may increase levels of uric acid in the body, which can cause gout or kidney stones

  • Heart disease—Risk of heart problems caused by doxorubicin may be increased

  • Liver disease—Effects of doxorubicin may be increased because of its slower removal from the body

Proper Use of Adriamycin


Doxorubicin is sometimes given together with certain other medicines. If you are receiving a combination of medicines, it is important that you receive each one at the proper time. If you are taking some of these medicines by mouth, ask your health care professional to help you plan a way to take them at the right times.


While you are using this medicine, your doctor may want you to drink extra fluids so that you will pass more urine. This will help prevent kidney problems and keep your kidneys working well.


Doxorubicin often causes nausea and vomiting. However, it is very important that you continue to receive the medication, even if you begin to feel ill. Ask your health care professional for ways to lessen these effects.


Dosing


The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.


The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.


Precautions While Using Adriamycin


It is very important that your doctor check your progress at regular visits to make sure that this medicine is working properly and to check for unwanted effects.


While you are being treated with doxorubicin, and after you stop treatment with it, do not have any immunizations (vaccinations) without your doctor's approval. Doxorubicin may lower your body's resistance, and there is a chance you might get the infection the immunization is meant to prevent. In addition, other persons living in your household should not take oral polio vaccine, since there is a chance they could pass the polio virus on to you. Also, avoid persons who have taken oral polio vaccine within the last several months. Do not get close to them, and do not stay in the same room with them for very long. If you cannot take these precautions, you should consider wearing a protective face mask that covers the nose and mouth.


Doxorubicin can temporarily lower the number of white blood cells in your blood, increasing the chance of getting an infection. It can also lower the number of platelets, which are necessary for proper blood clotting. If this occurs, there are certain precautions you can take, especially when your blood count is low, to reduce the risk of infection or bleeding:


  • If you can, avoid people with infections. Check with your doctor immediately if you think you are getting an infection or if you get a fever or chills, cough or hoarseness, lower back or side pain, or painful or difficult urination.

  • Check with your doctor immediately if you notice any unusual bleeding or bruising; black, tarry stools; blood in urine or stools; or pinpoint red spots on your skin.

  • Be careful when using a regular toothbrush, dental floss, or toothpick. Your medical doctor, dentist, or nurse may recommend other ways to clean your teeth and gums. Check with your medical doctor before having any dental work done.

  • Do not touch your eyes or the inside of your nose unless you have just washed your hands and have not touched anything else in the meantime.

  • Be careful not to cut yourself when you are using sharp objects such as a safety razor or fingernail or toenail cutters.

  • Avoid contact sports or other situations where bruising or injury could occur.

If doxorubicin accidentally seeps out of the vein into which it is injected, it may damage some tissues and cause scarring. Tell the doctor or nurse right away if you notice redness, pain, or swelling at the place of injection.


Adriamycin Side Effects


Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.



Check with your doctor immediately if any of the following side effects occur:


Less common
  • Fast or irregular heartbeat

  • pain at place of injection

  • shortness of breath

  • swelling of feet and lower legs

Rare
  • Black, tarry stools

  • blood in urine

  • pinpoint red spots on skin

  • unusual bleeding or bruising

  • wheezing

Check with your doctor as soon as possible if any of the following side effects occur:


More common
  • Sores in mouth and on lips

Less common
  • Cough or hoarseness accompanied by fever or chills

  • darkening or redness of skin (if you recently had radiation treatment)

  • fever or chills

  • joint pain

  • lower back or side pain accompanied by fever or chills

  • painful or difficult urination accompanied by fever or chills

  • red streaks along injected vein

  • stomach pain

Rare
  • Skin rash or itching

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:


More common
  • Nausea and vomiting

Less common
  • Darkening of soles, palms, or nails

  • diarrhea

Doxorubicin causes the urine to turn reddish in color, which may stain clothes. This is not blood. It is to be expected and only lasts for 1 or 2 days after each dose is given.


This medicine often causes a temporary and total loss of hair. After treatment with doxorubicin has ended, normal hair growth should return.


After you stop using this medicine, it may still produce some side effects that need attention. During this period of time, check with your doctor immediately if you notice the following side effects:


  • Fast or irregular heartbeat

  • shortness of breath

  • swelling of feet and lower legs

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.


Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

See also: Adriamycin side effects (in more detail)



The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.


The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.


More Adriamycin resources


  • Adriamycin Side Effects (in more detail)
  • Adriamycin Use in Pregnancy & Breastfeeding
  • Adriamycin Drug Interactions
  • Adriamycin Support Group
  • 1 Review for Adriamycin - Add your own review/rating


  • Adriamycin Prescribing Information (FDA)

  • Adriamycin MedFacts Consumer Leaflet (Wolters Kluwer)

  • Adriamycin Concise Consumer Information (Cerner Multum)

  • Doxorubicin Prescribing Information (FDA)

  • Doxorubicin Hydrochloride Monograph (AHFS DI)

  • Rubex Prescribing Information (FDA)



Compare Adriamycin with other medications


  • Acute Lymphoblastic Leukemia
  • Acute Myeloblastic Leukemia
  • Bladder Cancer
  • Breast Cancer
  • Cancer
  • Hodgkin's Lymphoma
  • Lung Cancer
  • Lymphoma
  • Multiple Myeloma
  • Neuroblastoma
  • Osteosarcoma
  • Ovarian Cancer
  • Soft Tissue Sarcoma
  • Stomach Cancer
  • Thyroid Cancer
  • Wilms' Tumor

Tuesday, 10 July 2012

Propylthiouracil


Class: Antithyroid Agents
ATC Class: H03BA02
VA Class: HS852
CAS Number: 51-52-5



  • Severe liver injury and acute liver failure, in some cases requiring liver transplantation or resulting in death, reported in adult and pediatric patients.109 (See Hepatotoxicity under Cautions.)




  • Reserve propylthiouracil for patients who cannot tolerate methimazole and for whom radioactive iodine therapy or surgery are not appropriate for the management of hyperthyroidism.109 (See Hyperthyroidism under Uses.)




  • Propylthiouracil may be the treatment of choice when an antithyroid drug is indicated during or just prior to the first trimester of pregnancy because of the risk of fetal abnormalities associated with methimazole.109 (See Fetal/Neonatal Morbidity and also see Pregnancy under Cautions.)



REMS:


FDA approved a REMS for propylthiouracil (ptu) to ensure that the benefits of a drug outweigh the risks. However, FDA later rescinded REMS requirements. See the FDA REMS page () or the ASHP REMS Resource Center ().



Introduction

Antithyroid agent;109 b thiourea-derivative.b


Uses for Propylthiouracil


Hyperthyroidism


Used in patients with Graves’ disease with hyperthyroidism or toxic multinodular goiter who are intolerant of methimazole and for whom surgery or radioactive iodine therapy is not an appropriate treatment option.109


Amelioration of symptoms of hyperthyroidism in preparation for thyroidectomy or radioactive iodine therapy in patients who are intolerant of methimazole.109


Propylthiouracil is associated with a higher risk for clinically serious or fatal liver injury compared with methimazole in adult and pediatric patients; therefore, when initiating hyperthyroid treatment, reserve propylthiouracil for patients who cannot tolerate methimazole and for whom radioactive iodine therapy or surgery are not appropriate for the management of hyperthyroidism.100 112 100 103 107 109 112 (See Boxed Warning and also see Hepatotoxicity under Cautions.)


Not recommended for use in pediatric patients except in rare instances in which methimazole is not well tolerated and surgery or radioactive iodine therapy are not appropriate therapies.100 103 106 109 112 (See Pediatric Use under Cautions.)


May be the treatment of choice when an antithyroid drug is indicated during or just prior to the first trimester of pregnancy because of the risk of fetal abnormalities associated with methimazole.100 103 107 108 109 112 For second and third trimesters, may be preferable to switch from propylthiouracil to methimazole because of the risk of maternal adverse effects associated with propylthiouracil (e.g., hepatotoxicity).109 (See Fetal/Neonatal Morbidity and also see Pregnancy under Cautions.)


Therapy with thioamide antithyroid agents maintains patient in euthyroid state for a period of several (generally 1–2) years until spontaneous remission occurs;b c however, spontaneous remission does not occur in all patients, and most eventually require ablative therapy (i.e., surgery, radioactive iodine).b Because thioamide antithyroid agents do not affect underlying cause of hyperthyroidism, generally avoid long-term use; minimum duration of therapy necessary before assessing whether spontaneous remission has occurred not clearly established.b


Therapy with propylthiouracil returns hyperthyroid patient to a normal metabolic state prior to thyroidectomy and controls the thyrotoxic crisis that may accompany thyroidectomy.b


Therapy with propylthiouracil controls the symptoms of hyperthyroidism before and during radioactive iodine therapy until the ablative effects of iodine occur.b However, pretreatment with thioamides may lower the cure rate and increase the need for subsequent doses of radioactive iodine.c


Thyrotoxic Crisis


May be used for management of thyrotoxic crisis;103 109 b c preferred over methimazole due to more rapid onset of effect (i.e., by inhibiting peripheral deiodination of thyroxine [T4] to triiodothyronine [T3], a dominant source of the hormone).103 c d Usually initiated before iodide (e.g., potassium iodide, strong iodine solution) therapy.b c d


Alcoholic Liver Disease


Has been studied in patients with alcoholic liver disease†.116


No substantial benefit has been demonstrated on any clinically important outcomes of alcoholic liver disease (e.g., all-cause mortality, liver-related mortality, complications associated with the liver disease, liver histology); currently available evidence does not support its use outside of randomized clinical studies.116


Propylthiouracil Dosage and Administration


General


Concomitant Therapy



  • May use a β-adrenergic blocking agent (e.g., propranolol) concomitantly to manage peripheral signs and symptoms of hyperthyroidism, particularly cardiovascular effects (e.g., tachycardia).b c



REMS Program



  • FDA has approved a Risk Evaluation and Mitigation Strategy (REMS) for propylthiouracil.112 114




  • The program consists of a medication guide that must be dispensed with every propylthiouracil prescription.112 113 114




  • The goal of the program is to inform patients about the serious risks (e.g., hepatotoxicity) associated with the use of propylthiouracil (see Cautions).114



Administration


Administer orally.109 b c May administer rectally† as extemporaneously prepared suppositories or enemas.c d o


Oral Administration


Administer total daily dosage orally in 3 equally divided doses at approximately 8-hour intervals.109 b c More frequent administration (e.g., at 4- or 6-hour intervals) may be necessary in some cases.b c


Dosage


Pediatric Patients


Hyperthyroidism

Oral

Generally not recommended for use in pediatric patients except in rare instances in which alternative therapies are not appropriate options.109 (See Pediatric Use under Cautions.) Although studies evaluating appropriate dosage regimens not conducted in pediatric population, manufacturer states that general practice would suggest initiation of therapy in children ≥6 years of age at 50 mg daily with careful upward titration based on clinical response and evaluation of TSH and free T4 concentrations.109


Severe liver injury reported with dosages as low as 50 mg daily, but most cases were associated with dosages of ≥300 mg daily.109 (See Hepatotoxicity under Cautions.)


Adults


Hyperthyroidism

Graves’ Disease with Hyperthyroidism or Toxic Multinodular Goiter

Oral

Initially, 300 mg daily.109 For patients with severe hyperthyroidism and/or very large goiters, initial dosage may be increased to 400 mg daily;109 occasionally, an initial dosage of 600–900 mg daily may be required.109


Continue therapy at initial dosage for about 4–8 weeks until symptoms resolve and euthyroidism is achieved.b c d j Then, gradually taper to a dosage that maintains euthyroidism.c d j


Usual maintenance dosage: Manufacturer recommends 100–150 mg daily.109


Most data support duration of 12–18 months.c l


Preparation for Thyroidectomy

Oral

Initially, 300 mg daily.109 For patients with severe hyperthyroidism and/or very large goiters, initial dosage may be increased to 400 mg daily;109 occasionally, an initial dosage of 600–900 mg daily may be required.109


Some clinicians recommend continuing therapy at initial dosage for about 6–8 weeks until euthyroidism is achieved; then add iodide therapy for 10–14 days (to decrease vascularity of thyroid gland) before surgery.j


Preparation for Radioactive Iodine Therapy

Oral

Initially, 300 mg daily.109 For patients with severe hyperthyroidism and/or very large goiters, usual initial dosage may be increased to 400 mg daily;109 occasionally, an initial dosage of 600–900 mg daily may be required.109


Some clinicians recommend continuing therapy at initial dosage for about 6–8 weeks until euthyroidism is achieved; then discontinue propylthiouracil ≥7 days before radioactive iodine therapy.c May reinstitute propylthiouracil 4 days after radioactive iodine therapy as needed (e.g., in patients with cardiac disease).c j


Thyrotoxic Crisis

Oral

Usually, 200 mg every 4–6 hours on the first day.b Once full control of symptoms is achieved, reduce dosage gradually to usual maintenance dosage.b


Special Populations


Hepatic Impairment


No specific dosage recommendations at this time.109


Renal Impairment


No specific dosage recommendations at this time.109


Geriatric Patients


No specific dosage recommendations at this time.109


Pregnancy


If used during pregnancy for the management of hyperthyroidism, a sufficient, but not excessive, dosage is necessary.109 Thyroid dysfunction diminishes in many women as pregnancy proceeds; reduction in dosage may be possible, and, in some patients, propylthiouracil can be discontinued several weeks or months before delivery.109 (See Pregnancy under Cautions and also see Hepatotoxicity under Cautions.)


Cautions for Propylthiouracil


Contraindications



  • Known hypersensitivity to propylthiouracil or any ingredient in the formulation.109 b



Warnings/Precautions


Warnings


Hepatotoxicity

Liver injury (including severe liver injury) resulting in hepatitis, liver failure (including acute liver failure), liver transplantation, or death reported in adult and pediatric patients.100 101 102 103 104 106 107 109 112 (See Boxed Warning.) FDA has concluded that use of propylthiouracil is associated with a higher risk for clinically serious or fatal liver injury compared with methimazole in both adult and pediatric patients.112


No cases of liver failure reported with use of methimazole in pediatric patients; therefore, propylthiouracil not recommended for use in pediatric patients except in rare instances in which methimazole is not well tolerated and surgery or radioactive iodine therapy are not appropriate therapies.109 (See Pediatric Use under Cautions.)


Cases of liver injury, including liver failure and death, reported in women receiving propylthiouracil during pregnancy.109 Two cases of in utero exposure with liver failure and death of a newborn also reported.109 Use of an alternative antithyroid drug (e.g., methimazole) may be advisable after the first trimester of pregnancy.109 (See Fetal/Neonatal Morbidity and also see Pregnancy under Cautions.)


Extent of propylthiouracil-induced hepatitis and true incidence of severe liver injury not known.104 107


Propylthiouracil-induced liver failure may occur at any time during therapy with a sudden onset, rapid progression, and a low chance of reversibility;103 104 liver failure has been observed after 6–450 days of propylthiouracil therapy (median: 120 days).107


Effect of dosage on risk of hepatotoxicity not clearly elucidated;104 however, reported average daily dosage associated with liver failure was approximately 300 mg in both children and adults.107


Closely monitor patients for signs and symptoms of liver injury (e.g., fatigue, weakness, vague abdominal pain, right upper quadrant pain, anorexia, pruritus, easy bruising, jaundice, pruritic rash, light-colored stool, dark urine, joint pain, bloating, nausea), particularly during the first 6 months following initiation of therapy.100 109 112 If such symptoms occur, immediately discontinue the drug, evaluate the patient for evidence of liver injury (including evaluation of liver function [bilirubin, alkaline phosphatase] and hepatocellular integrity [ALT, AST]), and provide supportive care.100 109 Some clinicians state that in patients with thioamide-induced hepatitis, rechallenge with alternative thioamide is not recommended because death has been reported.c


Routine biochemical monitoring of liver function (bilirubin, alkaline phosphatase) and hepatocellular integrity (ALT, AST) may not be effective in identifying patients at risk of liver failure and is not expected to attenuate risk of severe liver injury due to its rapid and unpredictable onset; however, should be performed in symptomatic patients.103 104 107 109


Hematologic Effects

Risk of agranulocytosis;109 b c d f usually occurs within first 3 months of therapy,109 but rarely may occur after 4 months of therapy.b Increased risk in patients >40 years of age;b d use with caution in such patients.b n


Leukopenia, thrombocytopenia, and aplastic anemia (pancytopenia) also may occur.109 b Hypoprothrombinemia and bleeding reported rarely with thioamides.c j (See Laboratory Monitoring under Cautions.)


Monitor patient carefully for signs or symptoms of illness (e.g., sore throat, skin eruptions, fever, chills, headache, general malaise), particularly during the early stages of therapy.b c d If fever, sore throat, or other signs or symptoms of illness occur, determine leukocyte and differential counts to assess whether agranulocytosis has developed.109 b d f When evaluating myelopoietic response to propylthiouracil, consider that leukopenia (i.e., WBC <4000/mm3) occurs in 10% of untreated hyperthyroid patients and is often associated with relative granulocytopenia.109 b


If agranulocytosis, aplastic anemia (pancytopenia), or fever is suspected, discontinue propylthiouracil and initiate appropriate supportive and symptomatic therapy.109 b c Obtain bone marrow indices.109


Hypothyroidism

May cause hypothyroidism necessitating routine monitoring of TSH and free T4 concentrations with dosage adjustments to maintain a euthyroid state.109


May cause fetal goiter and cretinism when administered to a pregnant woman, because the drug readily crosses the placenta.109 (See Fetal/Neonatal Morbidity and also see Pregnancy under Cautions.)


Fetal/Neonatal Morbidity

May cause fetal harm (i.e., induction of goiter, hypothyroidism, or cretinism).109 113 b


Congenital malformations reported approximately 3 times more often with prenatal exposure to methimazole compared with propylthiouracil.112 Distinct and consistent pattern of congenital malformations associated with the use of methimazole, but not with propylthiouracil, particularly craniofacial malformations (e.g., scalp epidermal aplasia [aplasia cutis], facial dysmorphism, choanal atresia).112 Specific birth defects were associated with use of methimazole during the first trimester of pregnancy and not found when the drug was administered later in pregnancy.112 FDA has not found a consistent pattern of birth defects associated with use of propylthiouracil and has concluded there is no convincing evidence of an association between propylthiouracil use and congenital malformations, even with use during the first trimester.112 (See Pregnancy under Cautions and also see Distribution under Pharmacokinetics.)


If used during pregnancy or if pregnancy occurs during therapy, apprise of rare potential hazard to the mother and fetus of liver damage; inform the patient of these potential risks and risks of methimazole-associated fetal malformations when considering antithyroid drug use during pregnancy.104 106 109 (See Hepatotoxicity under Cautions.)


Sensitivity Reactions


Cross-Sensitivity

Cross-sensitivity between thioamides likely to occurc f (i.e., in approximately 50% of patients switched from one thioamide agent to the other).d j


General Precautions


Laboratory Monitoring

Before initiating thioamide therapy, some clinicians recommend obtaining baseline T4 and TSH concentrations.c Baseline WBC with differential also may be useful in evaluating thioamide-induced adverse effects (e.g., leukopenia and/or agranulocytosis).c Routine biochemical monitoring of liver function (bilirubin, alkaline phosphatase) and hepatocellular integrity (ALT, AST) not expected to attenuate risk of severe liver injury, but should be performed in symptomatic patients.103 104 107 109 (See Hepatotoxicity under Cautions.)


Monitor thyroid function periodically109 b (e.g., 4–6 weeks after initiation of therapy and after any dosage adjustmentsc ); decrease dosage if TSH is elevated.109 b Once euthyroidism is achieved, monitor thyroid function every 3–6 months.c


Determine leukocyte and differential counts in patients who develop any signs or symptoms of illness (e.g., fever, sore throat) during therapy.b f


Consider monitoring PT during therapy, particularly before surgical procedures, because of possible risk of hypoprothrombinemia and bleeding.109 b


Dermatologic Effects

Exfoliative dermatitis reported.109 If exfoliative dermatitis is suspected, discontinue propylthiouracil and initiate appropriate supportive and symptomatic therapy.109 b


Immunologic Effects

Vasculitic syndrome associated with the presence of antineutrophil cytoplasmic antibody (ANCA) reported.109 d Manifestations of ANCA-positive vasculitis may include rapidly progressive glomerulonephritis (crescentic and pauci-immune necrotizing glomerulonephritis) sometimes leading to acute renal failure, fever, pulmonary infiltrates or alveolar hemorrhage, arthritis, skin ulcers, and leukocytoclastic vasculitis.109 d If ANCA-positive vasculitis is suspected, discontinue propylthiouracil promptly.109 d


Pulmonary Effects

Interstitial pneumonitis reported.109 b If interstitial pneumonitis is suspected, discontinue propylthiouracil.109


Specific Populations


Pregnancy

Category D.109 h (See Fetal/Neonatal Morbidity under Cautions and also see Distribution under Pharmacokinetics.)


Despite potential fetal hazard, antithyroid agents still considered therapy of choice for management of hyperthyroidism during pregnancy.108 d e Since methimazole may be associated with the rare development of fetal abnormalities (e.g., aplasia cutis, choanal atresia), propylthiouracil may be preferred when an antithyroid drug is indicated during organogenesis, in the first trimester of pregnancy, or just prior to the first trimester of pregnancy.100 103 106 107 108 109 (See Boxed Warning and also see Fetal/Neonatal Morbidity under Cautions.) May be preferable to switch from propylthiouracil to methimazole for the second and third trimesters, because of potential maternal adverse effects of propylthiouracil (e.g., hepatotoxicity).109 (See Hepatotoxicity under Cautions.) Not known if risk of methimazole-induced aplasia cutis or embryopathy outweighs risk of propylthiouracil-induced hepatotoxicity.104


When used in pregnancy, administer lowest effective dosage to maintain T4 concentrations at high end of normal range.108 c d e f As thyroid dysfunction improves during course of pregnancy, may reduce propylthiouracil dosage; in some patients, may discontinue propylthiouracil several weeks or months before delivery.109 b


If used during pregnancy or if patient becomes pregnant while receiving the drug, apprise of rare potential hazard to the mother and fetus of liver damage; inform the patient of these potential risks and risks of methimazole-associated fetal malformations when considering antithyroid drug use during pregnancy.104 106 109


Lactation

Distributed into milk to a small extent and, therefore, likely does not result in clinically important doses to the nursing infant.109 110 d h Mean amount of propylthiouracil distributed into milk during 4 hours following single oral 400-mg dose in 9 lactating women was 0.025% (range: 0.007–0.077%) of the administered dose.109 110 AAP and other clinicians consider propylthiouracil compatible with breast-feeding.108 d f h i


Adult Use

Patients >40 years of age: Use with caution because of increased risk of agranulocytosis.b n (See Hematologic Effects under Cautions.)


Pediatric Use

Postmarketing cases of severe liver injury, including hepatic failure requiring liver transplantation or resulting in death, reported in pediatric patients; however, no such reports observed with methimazole.109 117 Propylthiouracil not recommended for use in pediatric patients except in rare instances in which methimazole is not well tolerated and surgery or radioactive iodine therapy are not appropriate therapies.100 103 106 109 In addition, some experts state that alternative therapy should be considered for children who are currently receiving propylthiouracil and that it is reasonable and prudent to discontinue propylthiouracil use in children receiving this drug for the treatment of Graves’ disease.105 106


When propylthiouracil is used in children, inform parents and patients of risk of liver failure.109 If patients develop tiredness, nausea, anorexia, fever, pharyngitis, or malaise, immediately discontinue the drug, contact a clinician, and obtain WBC count, liver function tests, and transaminase concentrations.109 (See Hepatotoxicity under Cautions.)


Common Adverse Effects


Rash,109 b d f j l urticaria,109 b d pruritus,109 b abnormal hair loss,109 b skin pigmentation,109 b edema,109 b nausea,109 b f l vomiting,109 b l epigastric distress,109 b anorexia,f loss of taste109 b f or smell,f taste perversion,109 arthritis,f arthralgia,109 b d j myalgia,109 b paresthesia,109 b fever,f j l headache,109 b drowsiness,109 b neuritis,109 b vertigo,109 b jaundice,109 b sialadenopathy,109 b lymphadenopathy.109 b


Interactions for Propylthiouracil


Drugs Known to be Associated with Agranulocytosis


Use concomitantly with extreme caution.109 b


Specific Drugs


















Drug



Interaction



Comments



Anticoagulants, oral (e.g., warfarin)



Activity of oral anticoagulants (e.g., warfarin) may be increased because of the potential inhibition of vitamin K activity by propylthiouracil;109 however, increased and decreased PT/INR responses reported with concomitant use of propylthiouracil and warfarin115



Consider additional monitoring of PT/INR, particularly prior to surgery109



β-Adrenergic blocking agents (e.g., propranolol)



Possible increased clearance of β-adrenergic blocking agents with a high extraction ratio during hyperthyroid state109



Reduction of β-blocker dosage may be needed when patient becomes euthyroid109



Digitalis glycosides (e.g., digoxin)



Possible increased serum digitalis concentrations when hyperthyroid patients receiving a stable digitalis glycoside regimen become euthyroid109



Reduction of digitalis glycoside dosage may be needed when patient becomes euthyroid109



Theophylline



Possible decreased theophylline clearance when hyperthyroid patients on a stable theophylline regimen become euthyroid109



Reduction of theophylline dosage may be needed when patient becomes euthyroid109


Propylthiouracil Pharmacokinetics


Absorption


Bioavailability


Rapidly and readily absorbed from the GI tract following oral administration.109 b d j Peak plasma concentrations attained within 1–2 hours;b d j however, plasma concentrations do not appear to correlate with therapeutic effects.b


Bioavailability is approximately 75%.b


Onset

Slow onset because thioamides block synthesis (rather than release) of thyroid hormones; some symptomatic improvement should be noted 2–3 weeks after initiation of therapy.c


Duration

12–24 hours.d


Distribution


Extent


Distribution into human body tissues and fluids not fully characterized; however, drug appears to be concentrated in the thyroid gland.b


Readily crosses the placenta.109 b d e f h (See Fetal/Neonatal Morbidity and also Pregnancy under Cautions.)


Distributed into milk to a small extent;109 b h extent of distribution is about 0.007–0.077% of a single orally administered dose.109 110 111 b (See Lactation under Cautions.)


Plasma Protein Binding

Approximately 80–90%.d h


Elimination


Metabolism


Extensively metabolized to its glucuronide conjugate and other minor metabolites.109 b


Elimination Route


35% of dose excreted in urine as unchanged drug and metabolites within 24 hours.109 b


Half-life


Approximately 1–2 hours.b c d


Stability


Storage


Oral


Tablets

15–30°C.109


Actions



  • Inhibits the synthesis of thyroid hormones109 d f h l by interfering with the incorporation of iodine into tyrosyl residues of thyroglobulin;b j also inhibits the coupling of these iodotyrosyl residues to form iodothyronine. b


    Exact mechanism(s) not fully elucidated; however, propylthiouracil may interfere with the oxidation of iodide ion and iodotyrosyl groups.b




  • Limited evidence suggests that coupling reaction is more sensitive to antithyroid agents than the iodination reaction.b




  • Does not inhibit the action of thyroid hormones already formed and present in the thyroid gland or circulation; also does not interfere with the effectiveness of exogenously administered thyroid hormones.109 b Patients whose thyroid gland contains relatively high concentration of iodine (e.g., from prior ingestion or from administration during diagnostic radiologic procedures) may respond relatively slowly to antithyroid agents.b




  • Inhibits peripheral deiodination of T4 to T3.109 b c f h j



Advice to Patients



  • Under terms of FDA-approved REMS program, a medication guide must be dispensed with every propylthiouracil prescription.112 113 114 Importance of patient reading the manufacturer’s medication guide prior to initiating therapy with the drug and each time the prescription is refilled.112 113




  • Risk of liver failure.100 103 109 112 Importance of immediately discontinuing the drug and promptly contacting clinicians if signs and symptoms of liver injury or hepatic dysfunction (e.g., fatigue, weakness, vague abdominal pain, right upper quadrant pain, loss of appetite, itching, easy bruising, yellowing of the eyes or skin, pruritic rash, light-colored stool, dark urine, joint pain, bloating, nausea) occur, particularly in the first 6 months of therapy.100 103 109 112 (See Hepatotoxicity under Cautions.)




  • Importance of informing a clinician immediately if signs or symptoms of illness (e.g., sore throat, skin eruptions, fever, chills, headache, general malaise) occur.109 b c j (See Hematologic Effects under Cautions.)




  • Importance of patient not discontinuing propylthiouracil therapy unless instructed by their clinician.112




  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.109




  • Importance of women immediately informing clinicians if they are or plan to become pregnant or plan to breast-feed.109 112 Necessity for clinicians to advise women of rare potential hazard to the mother and fetus of propylthiouracil-associated liver toxicity, as well as risks of methimazole-associated fetal malformations when considering antithyroid drug use during pregnancy.104 106 109 (See Fetal/Neonatal Morbidity and also see Hepatotoxicity under Cautions.)




  • Importance of informing patients of other important precautionary information.109 (See Cautions.)



Preparations


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.


* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name













Propylthiouracil

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Oral



Tablets



50 mg*



Propylthiouracil Tablets


Comparative Pricing


This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 10/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.


Propylthiouracil 50MG Tablets (WEST-WARD): 90/$20.99 or 180/$34.97



Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.


The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions October 27, 2011. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.


† Use is not currently included in the labeling approved by the US Food and Drug Administration.




References



100. Food and Drug Administration. FDA Alert: Propylthiouracil-induced liver failure. Rockville, MD; 2009 Jun 4. From FDA website. Accessed 2009 Oct 28.



101. Food and Drug Administration. FDA News Release: FDA warns about serious liver injury associated with anti-thyroid drug. Rockville, MD; 2009 Jun 3. From FDA website. Accessed 2009 Oct 30.



102. Russo MW, Galanko JA, Shrestha R et al. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl. 2004; 10:1018-23. [PubMed 15390328]



103. Bahn RS, Burch HS, Cooper DS et al. The Role of Propylthiouracil in the Management of Graves' Disease in Adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid. 2009; 19:673-4. [PubMed 19583480]



104. Eunice Kennedy Shriver National Institute of Child Health and Human Development. Hepatic toxicity following treatment for pediatric Graves’ disease meeting: October 28, 2008. Conference proceeding. Available from website. Accessed 2009 Oct 30.



105. Rivkees SA, Mattison DR. Ending propylthiouracil-induced liver failure in children. N Engl J Med. 2009; 360:1574-5. [PubMed 19357418]



106. Rivkees SA, Mattison DR. Propylthiouracil (PTU) hepatotoxicity in children and recommendations for discontinuation of use. Int J Pediatr Endocrinol. 2009. Article ID 132041. DOI:10.1155/2009/132041.



107. Cooper DS, Rivkees SA. Putting propylthiouracil in perspective. J Clin Endocrinol Metab. 2009; 94:1881-2. [PubMed 19401361]



108. Abalovich M, Amino N, Barbour LA et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2007; 92:S1-47. [PubMed 17948378]



109. Dava Pharmaceuticals, Inc. Propylthiouracil tablets prescribing information. Fort Lee, NJ; 2010 Jan.



110. Kampmann JP, Johansen K, Hansen JM et al. Propylthiouracil in human milk. Revision of a dogma. Lancet. 1980; 1:736-7. [PubMed 6103158]



111. Low LC, Lang J, Alexander WD. Excretion of carbimazole and propylthiouracil in breast milk. Lancet. 1979; 2:1011. [PubMed 91730]



112. Food and Drug Administration. FDA drug safety communication: New boxed warning on severe liver injury with propylthiouracil. Rockville, MD; 2010 Apr 21. Available from FDA website (). Accessed 2010 Sep 8.



113. Dava Pharmaceuticals, Inc. Propylthiouracil tablets medication guide. Fort Lee, NJ; 2010 Mar.



114. Dava Pharmaceuticals, Inc. Propylthiouracil risk evaluation and mitigation strategy (REMS). Fort Lee, NJ; 2010 Mar 24. Available from FDA website (). Accessed 2010 Sep 8.



115. Bristol-Myers Squibb. Coumadin (warfarin sodium) tablets crystalline and Coumadin (warfarin sodium) for injection prescribing information. Princeton, NJ; 2010 Jan.



116. Rambaldi A, Gluud C. Propylthiouracil for alcoholic liver disease. Cochrane Database Syst Rev. 2005; :CD002800. [PubMed 16235302]



117. Rivkees SA, Szarfman A. Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in children. J Clin Endocrinol Metab. 2010; 95:3260-7. [PubMed 20427502]



b. AHFS drug information 2011. McEvoy GK, ed. Propylthiouracil. Bethesda, MD: American Society of Health-System Pharmacists; 2011.



c. Dong BJ. Endocrine Disorders. In: Koda-Kimble MA, Young LY, Kradjan WA et al, eds. Applied therapeutics: the clinical use of drugs. 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005.



d. Anon. Drugs for hypothyroidism and hyperthyroidism. Treat Guidel Med Lett. 2006; 4:17-24.



e. American Association of Clinical Endocrinologists. Medical